First, the depletion of CD4+ and CD8+ T cells entirely abrogates anti-CD27 activity, but not combination therapy, signifying that in combination, alternative, synergistic mechanisms of anti-tumor activity come into play. The gene discussed is CD8A; the disease is neoplasm.